An “ultra-restrictive” policy to reduce opioid prescribing to women who underwent major gynecologic cancer surgeries dramatically reduced opioid use.
A single-institution study of patients with advanced/recurrent EOCs found no overall survival differences for Caucasians and minorities who had participated in a clinical trial.
ACA Medicaid expansion benefited women younger than 65 who were diagnosed with a gynecologic cancer between 2011 and 2014, a SEER database analysis found.
Findings from the GOG-3007 study suggest everolimus plus letrozole might be effective in advanced persistent or recurrent endometrial carcinoma.
Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies.
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.
In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.
Treating women with stage IVB cervical cancer with whole pelvic radiation along with standard chemotherapy improved survival over chemotherapy alone in a retrospective study.